A pilot study on the efficacy of an Antiaris toxicaria subsp. africana (Engl.) C.C. Berg based Ghanaian herbal product in the management of peripheral neuropathy.

• Main Authors: Ronald Yeboah, Kwesi P. Thomford, Rudolph Mensah, Alfred A. Appiah, Ama K. Thomford, Augustine Ocloo
• Format: Article
• Language: English
• Published: Academic Association of Pharmaceutical Sciences from Antofagasta (ASOCIFA) 2019-01-01
• Series: Journal of Pharmacy & Pharmacognosy Research
• Subjects: Antiaris africana; efficacy studies; herbal medicines; neuropathy
• Online Access: http://jppres.com/jppres/pdf/vol7/jppres17.346_7.1.59.pdf

Context: Peripheral neuropathy is a common neurologic disease that accounts for a lot of physician visits. Aims: To evaluate the efficacy of a Ghanaian herbal product prepared from the stem bark of Antiaris toxicaria subsp. africana (known as Mist Antiaris) in the management of neurological disorders in patients clinically diagnosed with peripheral neuropathy. Methods: A prospective open label non-comparative study was undertaken involving 24 patients seen at the clinic of the Centre for Plant Medicine Research, Mampong-Akuapem. A modified Neuropathic Symptoms Score (NSS) and a visual analogue scale (VAS) using the standardized Wong-Baker faces rating scale (WBFRS) were used to grade each participant on the first day of visit. The VAS was subsequently used to grade and monitor improvements in the symptom characteristics of peripheral neuropathy at the fourth week and on the eighth week. Results: Mean age of participants involved in the study was 46.08 ± 2.77 years with the most significant comorbidity associated with participants being hypertension and type II diabetes, which accounted for 10 (41.66%) of the cases recorded. Baseline NSS indicated that 20 (83.0%) of the participants had severe symptoms and 4 (17.0%) reporting with moderate symptoms of neuropathy. Treatment resulted in an improvement of symptoms with a decline in mean VAS from a baseline of 6.04 ± 0.41 to 3.79 ± 0.74 on day 28 and 2.13 ± 0.93 by day 56. Conclusions: The results gathered from this pilot study indicates that the product Mist Antiaris has good prospects as an anti-neuropathic medication.